Impact of Severe Vitamin D Deficiency on Antibiotic Use in Hospitalized COPD Patients with Exacerbations: A
Boyu Li1, Meishan Liu2, Bingqing Ren1
1Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China.
Background:
Exacerbations of chronic obstructive pulmonary disease (ECOPD) often require antibiotic treatment. Vitamin D deficiency has been implicated in influencing the outcomes of ECOPD; however, its role in antibiotic usage during hospitalization remains unclear.
Patients And Methods:
We conducted a retrospective analysis of 125 hospitalized ECOPD patients, stratified into two groups based on the presence of severe vitamin D deficiency (SVDD, 25-hydroxyvitamin D < 10 ng/mL) and non-severe vitamin D deficiency (NSVDD). Clinical outcomes, including duration of antibiotic treatment, cumulative defined daily doses (cDDDs), hospital length of stay (LOS) and associated costs, were compared between subgroups. Multivariate linear regression was used to assess the association between 25-hydroxyvitamin D levels and antibiotic use, adjusting for demographic and clinical variables.
Results:
Patients with SVDD exhibited significantly longer durations of antibiotic use (13.50 vs. 11.00 days, P=0.023), higher cDDDs (16.16 vs. 12.00, P=0.012) and longer LOS (15.00 vs.12.00, P=0.026) compared to those with NSVDD. Patients with SVDD and pneumonia had more antibiotics use, longer LOS and higher cost than those with NSVDD and AECOPD (P<0.05). Multivariate linear regression analysis revealed that lower 25-hydroxyvitamin D levels were independently associated with increased antibiotic duration (coefficient -0.20, 95% CI -0.32, -0.08, P<0.001) and higher cDDDs (coefficient -0.24, 95% CI -0.46, -0.01, P=0.041) after adjustment, although the magnitude was smaller than that observed for some other variables.
Conclusion:
SVDD is independently associated with antibiotic burden in hospitalized COPD patients with exacerbation. Prospective studies are warranted to further explore this potential relationship and its clinical implications.
More Related Videos
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
Related Concept Videos
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...